Skip to content

Change in AR at other companies

Pfizer logo
PfizerPFE
$65.75M+141%
Amgen logo
AmgenAMGN
-$413M-132%
Janux Therapeutics logo
Janux TherapeuticsJANX
$35M
Perspective Therapeutics logo
Perspective TherapeuticsCATX
$52K+237%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$0+100%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$16.43M-463%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's change in AR?
CytomX Therapeutics (CTMX) reported change in AR of -$1.37M in Q1 2026.
How has CytomX Therapeutics's change in AR changed year-over-year?
CytomX Therapeutics's change in AR decreased by 19.2% year-over-year, from -$1.15M to -$1.37M.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.